|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
|
|---|---|---|
| Collaboration revenue | ||
| Operating expenses: | ||
| Research and development | ||
| General and administrative | ||
| Total operating expenses | ||
| Loss from operations | ||
| Other income, net | ||
| Net loss before income taxes | ||
| Benefit (provision) for income taxes | ||
| Net loss | ||
| Less: accretion of preferred stock to redemption value | ||
| Net loss attributable to common stockholders, basic | ||
| Net loss attributable to common stockholders, diluted | ||
| Weighted-average shares of common stock outstanding, basic | ||
| Weighted-average shares of common stock outstanding, diluted | ||
| Net loss per share attributable to common stockholders, basic | ||
| Net loss per share attributable to common stockholders, diluted | ||
| Other comprehensive loss: | ||
| Unrealized (loss) gain on available-for-sale debt securities | ||
| Total comprehensive loss |
Loading...
